Overview
Community Conversations: Real-World Strategies for Overcoming Disparities in Immunotherapy Cancer Care
Docuseries
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
These powerful and captivating stories follow real-world patients on their immunotherapy journeys. Multidisciplinary cancer care clinicians also provide insightful perspectives on these stories. Experts review the latest data and guidance to frame ongoing disparities with immunotherapy access and share strategies to overcome barriers and broaden therapeutic opportunities for underserved patient populations. Don’t miss this powerful documentary-style education that will help you close the ongoing immunotherapy access gaps and better ensure that patients receive the best possible care.
This activity is intended for oncologists, oncology allied healthcare professionals, social workers, case managers, nurse navigators, emergency medicine physicians, primary care physicians, and other relevant healthcare interested in immuno-oncology, cancer treatment, access to care, and health disparities.
Health inequities across varying socioeconomic and racial/ethnic groups continue to persist in cancer care, especially with access to lifesaving immunotherapy treatment. To ensure more optimized use of immunotherapies, clinicians need to understand the ongoing barriers and implement tactics to best address disparities within their own practice amongst their diverse patient populations with cancer.
Another significant gap related to optimal immunotherapy use relates to the proper recognition and management of immune-related adverse events (irAEs). All those on the interdisciplinary oncology team need to better grasp how to evaluate and mitigate irAEs, especially in patients with cancer who are challenged by health disparities.
Upon completion of this activity, participants will be able to:
• Identify health disparities and the need for patient support to achieve equitable care in the cancer care continuum
• Discuss expert recommendations on quality improvement checks that clinicians can implement in their health systems to recognize and eliminate cancer health disparities based on specific drivers of inequity
• Implement strategies to mitigate health disparities in all patients receiving I-O and experiencing irAEs
• Describe how to recognize and tailor management of irAEs in patient groups affected by inequalities and poor healthcare access
• Identify health disparities and the need for patient support to achieve equitable care in the cancer care continuum
• Discuss expert recommendations on quality improvement checks that clinicians can implement in their health systems to recognize and eliminate cancer health disparities based on specific drivers of inequity
• Implement strategies to mitigate health disparities in all patients receiving I-O and experiencing irAEs
• Describe how to recognize and tailor management of irAEs in patient groups affected by inequalities and poor healthcare access
This activity is supported by an educational grant from Bristol Myers Squibb.
• Gail
• Leonard and Suzanne
• Roseanne and Tom
• Leonard and Suzanne
• Roseanne and Tom
Narjust Duma, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Director of The Cancer Care Equity Program
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
Assistant Professor of Medicine
Harvard Medical School
Associate Director of The Cancer Care Equity Program
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
Lauren Gilson, BSN, RN
Oncology Nurse
Thomas Jefferson University Hospital
Philadelphia, PA
Jennifer Johnson, MD, PhD, FACP
Associate Professor
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, PA
Ana Maria Lopez, MPH, MD, MACP, FRCP
Professor and Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Chief of Cancer Services
Sidney Kimmel Cancer Center- Jefferson Health
Philadelphia, PA
Edith Peterson Mitchell, MD, MACP, FCPP, FRCP
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
Philadelphia, PA
Mark S. Morginstin, DO
Medical Oncologist
Einstein Healthcare Network
Einstein Medical Center Montgomery
East Norriton, PA
Jermine Mousa, PharmD
Clinical Oncology Pharmacy Manager
Einstein Medical Center Montgomery
East Norriton, PA
Lora Rhodes, MSW, LCSW
Senior Social Worker
Sidney Kimmel Cancer Center
Thomas Jefferson University Hospital
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Narjust Duma, MD (Faculty)
Consultant: Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Inc., NeoGenomics, and Pfizer
Jennifer Johnson, MD, PhD, FACP (Faculty)
Consultant: Foundation Medicine
Grant Support for Research: AstraZeneca, Bristol-Myers Squibb, and Merck & Co., Inc.
Ana Maria Lopez, MPH, MD, MPH, MACP, FRCP (Faculty)
Research Grant (Consultant): Bristol-Myers Squibb
The following faculty have no financial relationships to disclose:
• Lauren Gilson, BSN, RN (Faculty)
• Edith Peterson Mitchell, MD, MACP, FCPP, FRCP (Faculty)
• Mark S. Morginstin, DO (Faculty)
• Jermine Mousa, PharmD (Faculty)
• Lora Rhodes, MSW, LCSW (Faculty)
Patient Advocates Gail, Leonard and Suzanne, and Roseanne and Tom have nothing to disclose.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
